Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
| Autor: | Sebastian Bauer, J. C. Trent, Florence Duffaud, J.-Y. Blay, U. Bitz, Michael Montemurro, Hans Gelderblom, Daniel Pink, Jochen Schütte, Heikki Joensuu, Piotr Rutkowski |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Male Cancer Research Indoles Gastrointestinal stromal tumour Medizin Tyrosine kinase inhibitor urologic and male genital diseases Tyrosine-kinase inhibitor Piperazines 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Sunitinib Relapse Gastrointestinal Neoplasms Aged 80 and over 0303 health sciences GiST Progression Middle Aged Sorafenib female genital diseases and pregnancy complications 3. Good health Treatment Outcome Chemotherapy Adjuvant 030220 oncology & carcinogenesis Benzamides Disease Progression Imatinib Mesylate Salvage Female Tyrosine kinase medicine.drug GIST Adult Niacinamide medicine.medical_specialty medicine.drug_class Gastrointestinal Stromal Tumors Drug Administration Schedule 03 medical and health sciences Young Adult Internal medicine medicine Humans Pyrroles neoplasms Protein Kinase Inhibitors 030304 developmental biology Aged Retrospective Studies Salvage Therapy Performance status Dose-Response Relationship Drug business.industry Phenylurea Compounds Imatinib Nilotinib digestive system diseases Surgery Pyrimidines business |
| Zdroj: | European Journal of Cancer, 49(5), 1027-1031 |
| ISSN: | 1027-1031 |
| Popis: | Background Tyrosine kinase inhibitors (TKI) improve the outcome of patients with advanced gastrointestinal stromal tumour (GIST), but treatment failure is frequent, and prognosis then bleak. Smaller trials in this setting suggested activity for sorafenib, a multikinase inhibitor of receptor tyrosine kinases and RAF serine/threonine kinases. Patients and methods We retrospectively evaluated the efficacy of sorafenib, starting dose 400 mg twice daily, in a large community-based cohort of 124 patients treated in 12 European and one United States (U.S.) cancer centre. All but one patient had a WHO performance score 0–2. All had failed both imatinib and sunitinib, 68 patients nilotinib and 26 had failed investigational therapy, too. Results Twelve (10%) patients responded to sorafenib and 70 (57%) patients achieved disease stabilisation. Sorafenib was moderately tolerated, and toxicity reported in 56% of the patients. Rash, hand-foot-syndrome and diarrhea occurred frequently. Sorafenib dosage was reduced in a third of patients, but this did not have an impact on progression-free survival (PFS) ( p = 0.15). Median PFS was 6.4 months (95% confidence interval [CI], 4.6–8.0 months) and median overall survival (OS) 13.5 months (95% CI, 10.0–21.0 months). Patients with a good performance status and those who responded to sorafenib had a significant better PFS. Conclusion We conclude that sorafenib is active in GIST resistant to imatinib, sunitinib and nilotinib. These results warrant further investigation of sorafenib or similar molecules in GIST. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|